Showing results (791-800 of 964) with videos related to
Sort By:
Pageof 97
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.The Plant Cell|May 20, 2016
Genetic Analysis of Physcomitrella patens Identifies ABSCISIC ACID NON-RESPONSIVE, a Regulator of ABA Responses Unique to Basal Land Plants and Required for Desiccation ToleranceSean R Stevenson, Yasuko Kamisugi, Chi H Trinh, et al.The New England Journal of Medicine|December 21, 2007
Telbivudine versus lamivudine in patients with chronic hepatitis BChing-Lung Lai, Edward Gane, Yun-Fan Liaw, et al.Transplantation|October 19, 2018
International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver TransplantationMichael R Charlton, Edward J Gane, Aakash Shukla, et al.Alimentary Pharmacology & Therapeutics|November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis BJosef Wagner, Lilly Yuen, Margaret Littlejohn, et al.Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.Pageof 97